Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | CTPS1 | P17812 | 9/20 | 0.44 |
| ▸ | CKS1B | P61024 | 2/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.42 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30338582 | 1.00 | PTGS1 (0.46) | PTGS1PTGS2CTPS1CKS1BSKP2 | |
| SCHEMBL30620587 | 0.77 | CTPS1 (0.51) | PTGS1PTGS2CTPS1CKS1BSKP2 | |
| SCHEMBL25153928 | 0.76 | TSHR (0.38) | CTPS1EDNRAACHEABL1 | |
| SCHEMBL30339075 | 0.75 | TSHR (0.53) | PTGS1PTGS2CKS1BSKP2TDP1 | |
| SCHEMBL14830949 | 0.75 | TSHR (0.53) | PTGS1PTGS2CKS1BSKP2TDP1 | |
| SCHEMBL31678766 | 0.74 | PTGS1 (0.44) | PTGS1PTGS2CTPS1CKS1BSKP2 | |
| SCHEMBL30339221 | 0.74 | PTGS1 (0.44) | PTGS1PTGS2CTPS1CKS1BSKP2 | |
| SCHEMBL4740343 | 0.73 | ACHE (0.44) | EDNRAACHE | |
| SCHEMBL3432475 | 0.73 | EDNRA (0.46) | PTGS1PTGS2EDNRAACHE | |
| SCHEMBL30562266 | 0.73 | EDNRA (0.46) | PTGS1PTGS2EDNRAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269137-A1 | HDAC6 INHIBITORS FOR TREATMENT OF DILATED CARDIOMYOPATHY | TENAYA THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230086703-A1 | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | STEP PHARMA S.A.S. (FR) | 2023-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269137-A1 | HDAC6 INHIBITORS FOR TREATMENT OF DILATED CARDIOMYOPATHY | HDAC6, HDAC1, HDAC2 | PTGS1 3640/4885PTGS2 3703/4885CTPS1 1538/4885 |
| US-20230086703-A1 | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | CTPS1, CTPS2, CERS2 | PTGS1 551/4885PTGS2 897/4885CTPS1 1/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | PTGS1 655/4885PTGS2 975/4885CTPS1 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.